(vianews) - shares of medincell (cac 40: medcl.pa) dropped by a staggering 27.36% in 10 sessions from €9.32 to €6.77 at 02:06 est on thursday, following the last session's upward trend. cac 40 is dropping 0.09% to €7,399.44, following the last session's downward trend.
medincell's last close was €6.93, 34% below its 52-week high of €10.50.
about medincell
medincell s.a. develops various therapeutic solutions in france. it develops solutions based on bepo, a technology for long-acting injectable products based on proprietary copolymers and a biocompatible solvent, which solubilizes or suspends the active pharmaceutical ingredients. the company's products in development include mdc-irm, a risperidone extended-release injectable suspension completed phase iii trial for use in the treatment of schizophrenia; mdc-cwm, a sustained-release formulation of celecoxib in phase iii trials for use in the treatment of reduction of postoperative pain & inflammation; and mdc-tjk, a subcutaneous injection in phase iii trials for use in the treatment of schizophrenia. its product candidates in preclinical trials, such as mdc-ang, an antipsychotic product for use in the treatment of schizophrenia; mdc-ttg for covid-19 and its variants; mdc-grt for use in organ transplant; mdc-wwm for contraception; mdc-stm for use in malaria; mdc-kpt for use in acute pain for pets; and mdc-irm for use in neuroscience. the company was incorporated in 2003 and is based in jacou, france.
earnings per share
as for profitability, medincell has a trailing twelve months eps of €-0.93.
revenue growth
year-on-year quarterly revenue growth grew by 276.2%, now sitting on 8.52m for the twelve trailing months.
volume
today's last reported volume for medincell is 112807 which is 8.62% below its average volume of 75580.
more news about medincell (medcl.pa).